About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« C&E News - A Few Questions | Main | Bits And Pieces »

April 19, 2010

More on C&E News

Email This Entry

Posted by Derek

Thanks for all the comments to the previous post! And please, non-chemists who read or have a use for the magazine, please feel free to chime in as well.

Just to clear up some confusion, though, this is only an advisory position, and there are plenty of other people from academia and industry who also serve in the same capacity. I'm doing the same job I have been (and writing this blog the same way I have been as well!) Nothing's been affected, but it seems from the comments that some people have thought otherwise.

What will be affected around here this week is posting, which will be irregular. I'll try to get some things up, but it'll be haphazard. And I'll report back on the meeting with the C&E News folks as well.

Comments (3) + TrackBacks (0) | Category: Blog Housekeeping


1. Pharma Conduct Guy on April 19, 2010 11:00 PM writes...

Congratulations on being selected to serve in an advisory capacity. I'm sure that C&E News will find your perspective very helpful. Your clarification in this post is very helpful.

Permalink to Comment

2. p on April 20, 2010 5:53 AM writes...

I think the interest and bitterness present in the previous comments show that C&EN does have a role to fill and that, despite protests to the contrary, all hope is not lost. Chemists like chemistry and are frustrated at current state of affairs.

Permalink to Comment

3. Rhenium on April 20, 2010 9:52 AM writes...

Aren't you already on the advisory committee Derek?

I'm read the boring little column at the front about the various committee's and so forth and down the bottom under advisory committee is the name "Derek Lowe".

I don't have a CEN at hand because I throw them away almost as soon as I get them.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry